Accelerate kidney and rare disease drug development
A data-driven approach, from early investigation to commercialization, to increase kidney and rare disease drug development success.
Genetic data from 397 genes
Includes:
>8,250 Alport
> 8,500 ADPKD
>8,000 APOL1
Variant-level data for over 120,000 CKD patients
A clinical snapshot for >120,000 patients with CKD
Longitudinal clinical and claim data for each patient
De-identified patient dataset comprising of genetic findings, longitudinal claims, drug, and lab data
With over 120,000 patients tested with Renasight™ and more patients being tested everyday, Natera’s ever growing database delivers real-world insights that can accelerate the drug development lifecycle. Pharma partners can leverage this data to make informed decisions in kidney disease research, ensuring faster timelines and improved patient outcomes.
The Renasight™ database offers real-world insights at every stage in the drug development lifecycle
The Renasight™ database offers real-world insights at every stage in the drug development lifecycle
- Clinicogenomic datasets
- Patient cohorting and biomarker identification
- Real-world evidence for target validation
- Polygenic risk score insights (PRS)
- Drug Repurposing insights
- Clinicogenomic datasets
- Companion diagnostics
- Sponsored testing programs
- Real world comparator cohorts
- Longitudinal disease progression data
- Patient and site identification
- Post-market surveillance and pharmacovigilance data
- Genomic subpopulation analysis
- Indication expansion opportunities
- HCP and patient marketing support
- Patient cohorting
- HEOR data
- Real-world utilization and adoption insights
- Disease and therapy education for HCPs
- Genomic-driven pharmacovigilance
- Longitudinal patient tracking
- Subpopulation risk analysis
A data-driven approach to advance kidney disease drug discovery and patient outcomes
The Renasight™ clinicogenomic database supports every stage in the drug development lifecycle. Through data licensing, analytics and clinical trial support services, Natera empowers Pharma innovators to better understand the kidney disease population and address unmet medical needs.
Data Licensing
Access and use the Renasight database in clinical research within your organization.
Data Analytics
- Descriptive, diagnostic, predictive, and prescriptive analytics services provided by Natera data scientists
- Synthesize report findings in collaboration with Natera genetic counselors who specialize in kidney disease
Clinical Trial Support Services
- Site and principal investigator viability
- Patient matching
- Ad hoc analysis
Each of Natera’s pharma partners benefit from direct access to a dedicated team of experts to assist in providing tailored insights and data synthesis to support your research goals. This team includes Data Scientists and Genetic Counsellors who specialize in kidney disease.
Natera’s kidney disease data services can help:
- Determine asset viability with real-world patient data
- Optimize clinical trial design for target recruitment
- Expedite clinical trial enrollment with precise population insights
- Understand the patient journey to identify gaps and opportunities
- Hone commercial targeting for effective therapy deployment
- Provide disease state and therapy education for stakeholders
- Enable patient journey mapping to improve outcomes
Why the Renasight™ Database
Uniquely focused on kidney disease
Leverages the Renasight™ test, a 397 gene panel that can determine the cause of one’s chronic kidney disease (CKD)
Clinical-grade accuracy
A CLIA-validated next generation sequencing (NGS) test
Largest commercially available kidney disease database
De-identified data for >120,000 CKD patients
Data attributes proprietary to Natera
Information from test requisition forms as well as direct access to select patients and HCPs through Natera
Tailored Guidance
An expert data team comprised of data scientists and genetic counsellors specialized in kidney disease to assist with your data analysis
Natera uniquely combines expansive genetic datasets with longitudinal clinical data, creating unmatched precision and depth. Our end-to-end support from raw data licensing to actionable clinical insights help pharma innovators reduce costs, shorten timelines and enhance success rates in drug development.